Literature DB >> 7513620

V79 Chinese hamster lung cells resistant to the bis-alkylator bizelesin are multidrug-resistant.

R K Butryn1, K S Smith, E G Adams, I Abraham, J Stackpole, K E Sampson, B K Bhuyan.   

Abstract

Bizelesin (U-77779) is a highly potent bis-alkylating antitumor agent that is effective against several tumor systems in vitro and in vivo. V79 cells that were 125- to 250-fold resistant to bizelesin developed after constant exposure to gradually increasing concentrations of the drug. Resistant cells exhibited a multidrug-resistant phenotype and genotype as indicated by cross-resistant to several structurally and functionally unrelated drugs, e.g., colchicine, actinomycin D, and Adriamycin, and overexpression of mdr mRNA. Very low levels of cross-resistance to the alkylating agents cisplatin and melphalan were seen. Multidrug-resistant mouse leukemia (P388/Adriamycin-resistant) and human (KB/vinblastine-resistant) cells were also resistant to bizelesin. Bizelesin resistance was unstable and decreased when cells were grown in the absence of the drug. Resistant and sensitive cell lines had similar levels of glutathione, and bizelesin cytotoxicity for resistant cells was not markedly affected by treatment with buthionine sulfoximine. Cross-resistance between bizelesin and several of its analogs is reported.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513620     DOI: 10.1007/bf00686110

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  27 in total

Review 1.  Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy--a review.

Authors:  D J Waxman
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

2.  Genomic sequencing.

Authors:  G M Church; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

3.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

4.  In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.

Authors:  R K Johnson; M P Chitnis; W M Embrey; E B Gregory
Journal:  Cancer Treat Rep       Date:  1978-10

5.  Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines.

Authors:  J R Riordan; K Deuchars; N Kartner; N Alon; J Trent; V Ling
Journal:  Nature       Date:  1985 Aug 29-Sep 4       Impact factor: 49.962

6.  Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065.

Authors:  J P McGovren; G L Clarke; E A Pratt; T F DeKoning
Journal:  J Antibiot (Tokyo)       Date:  1984-01       Impact factor: 2.649

7.  Lethality, DNA alkylation, and cell cycle effects of adozelesin (U-73975) on rodent and human cells.

Authors:  B K Bhuyan; K S Smith; E G Adams; G L Petzold; J P McGovren
Journal:  Cancer Res       Date:  1992-10-15       Impact factor: 12.701

8.  A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells.

Authors:  I Pastan; M M Gottesman; K Ueda; E Lovelace; A V Rutherford; M C Willingham
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

9.  Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification.

Authors:  D W Shen; A Fojo; J E Chin; I B Roninson; N Richert; I Pastan; M M Gottesman
Journal:  Science       Date:  1986-05-02       Impact factor: 47.728

10.  P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype.

Authors:  G J Badiner; B C Moy; K S Smith; W G Tarpley; V E Groppi; B K Bhuyan
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

View more
  1 in total

Review 1.  PVP-coated, negatively charged silver nanoparticles: A multi-center study of their physicochemical characteristics, cell culture and in vivo experiments.

Authors:  Sebastian Ahlberg; Alexandra Antonopulos; Jörg Diendorf; Ralf Dringen; Matthias Epple; Rebekka Flöck; Wolfgang Goedecke; Christina Graf; Nadine Haberl; Jens Helmlinger; Fabian Herzog; Frederike Heuer; Stephanie Hirn; Christian Johannes; Stefanie Kittler; Manfred Köller; Katrin Korn; Wolfgang G Kreyling; Fritz Krombach; Jürgen Lademann; Kateryna Loza; Eva M Luther; Marcelina Malissek; Martina C Meinke; Daniel Nordmeyer; Anne Pailliart; Jörg Raabe; Fiorenza Rancan; Barbara Rothen-Rutishauser; Eckart Rühl; Carsten Schleh; Andreas Seibel; Christina Sengstock; Lennart Treuel; Annika Vogt; Katrin Weber; Reinhard Zellner
Journal:  Beilstein J Nanotechnol       Date:  2014-11-03       Impact factor: 3.649

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.